Navigation Links
Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Date:10/17/2010

able and one or more research and development programs could unexpectedly fail; (iv) Nektar's patent applications for its proprietary or partner drug candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (v) the outcome of any existing or future intellectual property or other litigation related to Nektar's proprietary drug candidates including without limitation NKTR-181.  Other important risks and uncertainties are detailed in Nektar's reports and other filings with the Securities and Exchange Commission, including without limitation, those risks and uncertainties set forth in Nektar's Form 10-Q for the quarter ended June 30, 2010, filed on July 29, 2010. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

References:

(1) Harstall, C. How prevalent is chronic pain? Pain Clinical Updates X, 1–4 (2003).

(2)  IMS, NSP, NPA and Defined Health 2010 Estimates.

(3)  Melnikova, I, Pain Market, Nature Reviews Drug Discovery, Volume 9, 589-90 (August 2010).

(4) Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, "Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Analgesics", July 23-4, 2010.

(5) Morbidity and Mortality Weekly Report (MMWR), Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States, 2004—2008, 59(23);705-709 (June 2010).


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... PHILADELPHIA , Sept. 19, 2014  PCI ... Services International (Biotec).  Biotec is a leading provider ... Services headquartered in Bridgend, Wales ... .  The addition significantly expands PCI,s presence in ... medicinal products by adding packaging, storage and distribution ...
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... U.S. Food and Drug Administration (FDA) approved ... of INTELENCE ® (etravirine), a non-nucleoside reverse transcriptase ... virus (HIV-1) in treatment-experienced adults with resistance to an ... The recommended oral dose of INTELENCE tablets is 200 ...
... KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech ... with its subsidiary collectively as the "Group" - 801.HK), ... announce that the Company has obtained the approvals from ... Futures Bureau for its proposed offering and listing of ...
Cached Medicine Technology:FDA Approves New Dosage Strength for INTELENCE® 2FDA Approves New Dosage Strength for INTELENCE® 3FDA Approves New Dosage Strength for INTELENCE® 4FDA Approves New Dosage Strength for INTELENCE® 5Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering 2
(Date:9/19/2014)... September 19, 2014 The Alliance ... partnership with the National Fire Protection Association (NFPA), ... collaboration, formalized today in a Memorandum of Understanding ... factories, workers and other stakeholders with information, guidance ... protect the health and safety of workers in ...
(Date:9/19/2014)... 2014 "I have difficulty putting in ... to stretching the skin around my eyes during the ... me to design a more convenient method of performing ... provides a quicker, easier, more sanitary method of putting ... this task manually, saves time and effort, and helps ...
(Date:9/19/2014)... approaches to reducing poverty that help children and ... advocates, and foundations. By combining education and training ... jobs that offer a path out of poverty ... these programs aim to improve the life opportunities ... report from the National Center for Children in ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- When it comes ... in the United States, while the District of Columbia ... the past decade, deaths from gun-related violence -- including ... the United States, the study revealed. Hawaii,s rate was ... of the spectrum, the District of Columbia had the ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2
... Dietary Guidelines (i.e., men who usually drink more than two ... one drink per day) or those who binge drink are ... new study accepted for publication in The Endocrine Society,s ... metabolic syndrome consists of a series of risk factors and ...
... Shows Overuse of Technology Is Wreaking ... Havoc on Romance -, ... juggling lengthy to-do lists, jam-packed schedules, and the 24/7,demands of children and ... wired lifestyle allows people to stay,connected with more friends, family and co-workers ...
... following news tips are based on poster and oral presentations ... in Chicago from July 26 to July 31. Each presentation ... Brain Atrophy and Biomarkers May Help Identify People at Risk ... Department of Psychiatry, NYU Langone Medical Center , EMBARGOED FOR ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ) updates and corrects ... 2008 net income is expected to,range from approximately $13.1 million ... which is changed from the previously announced net,income of $11.5 ... per,share., ABOUT VNUS MEDICAL TECHNOLOGIES, INC., VNUS is ...
... and Charitable Care and Coverage, OAKLAND, Calif., ... has approved more than 415 community benefit grants ... quarter of 2008.,The quarter,s contributions continue to support ... measurable impact on the health of,its communities., ...
... PORTLAND, Ore., July 29 Sometimes the simplest ... to health care --,are the most difficult., Regence ... company has launched a Web site that enables consumers ... health-related topics., The video cards are part of ...
Cached Medicine News:Health News:Drinking in excess associated with increased risk for metabolic syndrome 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 3Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 4Health News:New Alzheimer's predictors advance earlier detection 2Health News:New Alzheimer's predictors advance earlier detection 3Health News:New Alzheimer's predictors advance earlier detection 4Health News:New Alzheimer's predictors advance earlier detection 5Health News:New Alzheimer's predictors advance earlier detection 6Health News:New Alzheimer's predictors advance earlier detection 7Health News:New Alzheimer's predictors advance earlier detection 8Health News:VNUS Revises Upward Full-Year 2008 Net Income Guidance 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 3Health News:Regence Video Cards Help Start Important Health Conversations With Friends, Family 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: